Saphris
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVE
To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic…
The causes and origins of pica remain unknown and are the source of speculation and heated debate. Bariatric surgery patients are…
Asenapine (Saphris®) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the…
Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of…
T he US health system is under reform. More than ever, busy practitioners need help in prescribing drugs more knowledgeably and…
Antipsychotic drugs are commonly prescribed for a variety of psychiatric conditions. In addition to individuals with…
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute…
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously…
Antipsychotic agents Asenapine (Saphris—Schering) and iloperidone (Fanapt—Vanda) are new atypical antipsychotic agents that join…